<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2007-10-21" updated="2020-01-02">
  <drugbank-id primary="true">DB04891</drugbank-id>
  <name>Becocalcidiol</name>
  <description>Becocalcidiol is a vitamin D(3) analogue which has not caused hypercalcaemia or significant irritation in preclinical trials.</description>
  <cas-number>524067-21-8</cas-number>
  <unii>N75R59YD0F</unii>
  <average-mass>344.5307</average-mass>
  <monoisotopic-mass>344.271530396</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A2840</ref-id>
        <pubmed-id>17596167</pubmed-id>
        <citation>Helfrich YR, Kang S, Hamilton TA, Voorhees JJ: Topical becocalcidiol for the treatment of psoriasis vulgaris: a randomized, placebo-controlled, double-blind, multicentre study. Br J Dermatol. 2007 Aug;157(2):369-74. Epub 2007 Jun 26.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>For topical treatment of psoriasis and psoriatic disorders.</indication>
  <pharmacodynamics>Becocalcidiol (formerly QRX-101) is a novel vitamin D analogue for the treatment of mild to moderate psoriasis. In clinical and preclinical studies, becocalcidiol has been well tolerated with a low incidence of skin irritation. Based on the completed Phase IIb study, becocalcidiol was statistically superior to placebo in reducing plaque and did not result in excessive blood calcium levels, a side effect of existing calcitriol topical treatments for psoriasis.</pharmacodynamics>
  <mechanism-of-action>The mechanism of action of becocalcidiol in the treatment of psoriasis is accounted for by an antiproliferative activity for keratinocytes and the stimulation of epidermal cell differentiation.</mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of organic compounds known as vitamin d and derivatives. These are compounds containing a secosteroid backbone, usually secoergostane or secocholestane.</description>
    <direct-parent>Vitamin D and derivatives</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Lipids and lipid-like molecules</superclass>
    <class>Steroids and steroid derivatives</class>
    <subclass>Vitamin D and derivatives</subclass>
    <alternative-parent>Cyclic alcohols and derivatives</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Secondary alcohols</alternative-parent>
    <alternative-parent>Triterpenoids</alternative-parent>
    <substituent>Alcohol</substituent>
    <substituent>Aliphatic homopolycyclic compound</substituent>
    <substituent>Cyclic alcohol</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Polycyclic triterpenoid</substituent>
    <substituent>Secondary alcohol</substituent>
    <substituent>Triterpenoid</substituent>
  </classification>
  <salts/>
  <synonyms/>
  <products/>
  <international-brands>
    <international-brand>
      <name>Asord</name>
      <company>QuatRx</company>
    </international-brand>
  </international-brands>
  <mixtures/>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Cholestanes</category>
      <mesh-id>D002776</mesh-id>
    </category>
    <category>
      <category>Cholestenes</category>
      <mesh-id>D002782</mesh-id>
    </category>
    <category>
      <category>Fused-Ring Compounds</category>
      <mesh-id>D000072473</mesh-id>
    </category>
    <category>
      <category>Lipids</category>
      <mesh-id>D008055</mesh-id>
    </category>
    <category>
      <category>Membrane Lipids</category>
      <mesh-id>D008563</mesh-id>
    </category>
    <category>
      <category>Secosteroids</category>
      <mesh-id>D012632</mesh-id>
    </category>
    <category>
      <category>Steroids</category>
      <mesh-id>D013256</mesh-id>
    </category>
    <category>
      <category>Sterols</category>
      <mesh-id>D013261</mesh-id>
    </category>
    <category>
      <category>Vitamin D and Analogues</category>
      <mesh-id>D004100</mesh-id>
    </category>
    <category>
      <category>Vitamins</category>
      <mesh-id>D014815</mesh-id>
    </category>
    <category>
      <category>Vitamins (Fat Soluble)</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages/>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries>
    <pdb-entry>1rkg</pdb-entry>
  </pdb-entries>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB06723</drugbank-id>
      <name>Aluminum hydroxide</name>
      <description>The serum concentration of Aluminum hydroxide can be increased when it is combined with Becocalcidiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01406</drugbank-id>
      <name>Danazol</name>
      <description>Danazol may increase the hypercalcemic activities of Becocalcidiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00364</drugbank-id>
      <name>Sucralfate</name>
      <description>The serum concentration of Sucralfate can be increased when it is combined with Becocalcidiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01083</drugbank-id>
      <name>Orlistat</name>
      <description>Orlistat can cause a decrease in the absorption of Becocalcidiol resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00653</drugbank-id>
      <name>Magnesium sulfate</name>
      <description>The serum concentration of Magnesium sulfate can be increased when it is combined with Becocalcidiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01377</drugbank-id>
      <name>Magnesium oxide</name>
      <description>The serum concentration of Magnesium oxide can be increased when it is combined with Becocalcidiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01397</drugbank-id>
      <name>Magnesium salicylate</name>
      <description>The serum concentration of Magnesium salicylate can be increased when it is combined with Becocalcidiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08938</drugbank-id>
      <name>Magaldrate</name>
      <description>The serum concentration of Magaldrate can be increased when it is combined with Becocalcidiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09104</drugbank-id>
      <name>Magnesium hydroxide</name>
      <description>The serum concentration of Magnesium hydroxide can be increased when it is combined with Becocalcidiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09281</drugbank-id>
      <name>Magnesium trisilicate</name>
      <description>The serum concentration of Magnesium trisilicate can be increased when it is combined with Becocalcidiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09407</drugbank-id>
      <name>Magnesium chloride</name>
      <description>The serum concentration of Magnesium chloride can be increased when it is combined with Becocalcidiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09481</drugbank-id>
      <name>Magnesium carbonate</name>
      <description>The serum concentration of Magnesium carbonate can be increased when it is combined with Becocalcidiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09511</drugbank-id>
      <name>Talc</name>
      <description>The serum concentration of Talc can be increased when it is combined with Becocalcidiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11110</drugbank-id>
      <name>Magnesium citrate</name>
      <description>The serum concentration of Magnesium citrate can be increased when it is combined with Becocalcidiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13249</drugbank-id>
      <name>Magnesium silicate</name>
      <description>The serum concentration of Magnesium silicate can be increased when it is combined with Becocalcidiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13322</drugbank-id>
      <name>Hydrotalcite</name>
      <description>The serum concentration of Hydrotalcite can be increased when it is combined with Becocalcidiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13359</drugbank-id>
      <name>Magnesium aspartate</name>
      <description>The serum concentration of Magnesium aspartate can be increased when it is combined with Becocalcidiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13486</drugbank-id>
      <name>Magnesium peroxide</name>
      <description>The serum concentration of Magnesium peroxide can be increased when it is combined with Becocalcidiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13749</drugbank-id>
      <name>Magnesium gluconate</name>
      <description>The serum concentration of Magnesium gluconate can be increased when it is combined with Becocalcidiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13786</drugbank-id>
      <name>Magnesium orotate</name>
      <description>The serum concentration of Magnesium orotate can be increased when it is combined with Becocalcidiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14513</drugbank-id>
      <name>Magnesium</name>
      <description>The serum concentration of Magnesium can be increased when it is combined with Becocalcidiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14514</drugbank-id>
      <name>Magnesium levulinate</name>
      <description>The serum concentration of Magnesium levulinate can be increased when it is combined with Becocalcidiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14515</drugbank-id>
      <name>Magnesium lactate</name>
      <description>The serum concentration of Magnesium lactate can be increased when it is combined with Becocalcidiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00390</drugbank-id>
      <name>Digoxin</name>
      <description>The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Becocalcidiol is combined with Digoxin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00511</drugbank-id>
      <name>Acetyldigitoxin</name>
      <description>The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Becocalcidiol is combined with Acetyldigitoxin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01078</drugbank-id>
      <name>Deslanoside</name>
      <description>The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Becocalcidiol is combined with Deslanoside.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01092</drugbank-id>
      <name>Ouabain</name>
      <description>The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Becocalcidiol is combined with Ouabain.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01396</drugbank-id>
      <name>Digitoxin</name>
      <description>The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Becocalcidiol is combined with Digitoxin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12843</drugbank-id>
      <name>Oleandrin</name>
      <description>The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Becocalcidiol is combined with Oleandrin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13240</drugbank-id>
      <name>Cymarin</name>
      <description>The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Becocalcidiol is combined with Cymarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13307</drugbank-id>
      <name>Proscillaridin</name>
      <description>The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Becocalcidiol is combined with Proscillaridin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13401</drugbank-id>
      <name>Metildigoxin</name>
      <description>The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Becocalcidiol is combined with Metildigoxin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13467</drugbank-id>
      <name>Lanatoside C</name>
      <description>The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Becocalcidiol is combined with Lanatoside C.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13537</drugbank-id>
      <name>Gitoformate</name>
      <description>The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Becocalcidiol is combined with Gitoformate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13691</drugbank-id>
      <name>Acetyldigoxin</name>
      <description>The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Becocalcidiol is combined with Acetyldigoxin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13756</drugbank-id>
      <name>Peruvoside</name>
      <description>The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Becocalcidiol is combined with Peruvoside.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11057</drugbank-id>
      <name>Mineral oil</name>
      <description>Mineral oil can cause a decrease in the absorption of Becocalcidiol resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00232</drugbank-id>
      <name>Methyclothiazide</name>
      <description>The risk or severity of hypercalcemia can be increased when Methyclothiazide is combined with Becocalcidiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00436</drugbank-id>
      <name>Bendroflumethiazide</name>
      <description>The risk or severity of hypercalcemia can be increased when Bendroflumethiazide is combined with Becocalcidiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00562</drugbank-id>
      <name>Benzthiazide</name>
      <description>The risk or severity of hypercalcemia can be increased when Benzthiazide is combined with Becocalcidiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00606</drugbank-id>
      <name>Cyclothiazide</name>
      <description>The risk or severity of hypercalcemia can be increased when Cyclothiazide is combined with Becocalcidiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00774</drugbank-id>
      <name>Hydroflumethiazide</name>
      <description>The risk or severity of hypercalcemia can be increased when Hydroflumethiazide is combined with Becocalcidiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00880</drugbank-id>
      <name>Chlorothiazide</name>
      <description>The risk or severity of hypercalcemia can be increased when Chlorothiazide is combined with Becocalcidiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00999</drugbank-id>
      <name>Hydrochlorothiazide</name>
      <description>The risk or severity of hypercalcemia can be increased when Hydrochlorothiazide is combined with Becocalcidiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01021</drugbank-id>
      <name>Trichlormethiazide</name>
      <description>The risk or severity of hypercalcemia can be increased when Trichlormethiazide is combined with Becocalcidiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01119</drugbank-id>
      <name>Diazoxide</name>
      <description>The risk or severity of hypercalcemia can be increased when Diazoxide is combined with Becocalcidiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01324</drugbank-id>
      <name>Polythiazide</name>
      <description>The risk or severity of hypercalcemia can be increased when Polythiazide is combined with Becocalcidiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13430</drugbank-id>
      <name>Mebutizide</name>
      <description>The risk or severity of hypercalcemia can be increased when Mebutizide is combined with Becocalcidiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13532</drugbank-id>
      <name>Cyclopenthiazide</name>
      <description>The risk or severity of hypercalcemia can be increased when Cyclopenthiazide is combined with Becocalcidiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00136</drugbank-id>
      <name>Calcitriol</name>
      <description>The risk or severity of adverse effects can be increased when Calcitriol is combined with Becocalcidiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00146</drugbank-id>
      <name>Calcifediol</name>
      <description>The risk or severity of adverse effects can be increased when Calcifediol is combined with Becocalcidiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00153</drugbank-id>
      <name>Ergocalciferol</name>
      <description>The risk or severity of adverse effects can be increased when Ergocalciferol is combined with Becocalcidiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00169</drugbank-id>
      <name>Cholecalciferol</name>
      <description>The risk or severity of adverse effects can be increased when Cholecalciferol is combined with Becocalcidiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00910</drugbank-id>
      <name>Paricalcitol</name>
      <description>The risk or severity of adverse effects can be increased when Paricalcitol is combined with Becocalcidiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01070</drugbank-id>
      <name>Dihydrotachysterol</name>
      <description>The risk or severity of adverse effects can be increased when Dihydrotachysterol is combined with Becocalcidiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01436</drugbank-id>
      <name>Alfacalcidol</name>
      <description>The risk or severity of adverse effects can be increased when Alfacalcidol is combined with Becocalcidiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04258</drugbank-id>
      <name>Seocalcitol</name>
      <description>The risk or severity of adverse effects can be increased when Seocalcitol is combined with Becocalcidiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04796</drugbank-id>
      <name>Inecalcitol</name>
      <description>The risk or severity of adverse effects can be increased when Inecalcitol is combined with Becocalcidiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05295</drugbank-id>
      <name>Eldecalcitol</name>
      <description>The risk or severity of adverse effects can be increased when Becocalcidiol is combined with Eldecalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06117</drugbank-id>
      <name>1alpha,24S-Dihydroxyvitamin D2</name>
      <description>The risk or severity of adverse effects can be increased when Becocalcidiol is combined with 1alpha,24S-Dihydroxyvitamin D2.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06194</drugbank-id>
      <name>Elocalcitol</name>
      <description>The risk or severity of adverse effects can be increased when Becocalcidiol is combined with Elocalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06272</drugbank-id>
      <name>Maxacalcitol</name>
      <description>The risk or severity of adverse effects can be increased when Becocalcidiol is combined with Maxacalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06410</drugbank-id>
      <name>Doxercalciferol</name>
      <description>The risk or severity of adverse effects can be increased when Becocalcidiol is combined with Doxercalciferol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11094</drugbank-id>
      <name>Vitamin D</name>
      <description>The risk or severity of adverse effects can be increased when Becocalcidiol is combined with Vitamin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13097</drugbank-id>
      <name>1alpha-Hydroxyvitamin D5</name>
      <description>The risk or severity of adverse effects can be increased when Becocalcidiol is combined with 1alpha-Hydroxyvitamin D5.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13689</drugbank-id>
      <name>Tacalcitol</name>
      <description>The risk or severity of adverse effects can be increased when Becocalcidiol is combined with Tacalcitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00258</drugbank-id>
      <name>Calcium acetate</name>
      <description>The risk or severity of adverse effects can be increased when Calcium acetate is combined with Becocalcidiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00326</drugbank-id>
      <name>Calcium glucoheptonate</name>
      <description>The risk or severity of adverse effects can be increased when Calcium glucoheptonate is combined with Becocalcidiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01164</drugbank-id>
      <name>Calcium chloride</name>
      <description>The risk or severity of adverse effects can be increased when Calcium Chloride is combined with Becocalcidiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01373</drugbank-id>
      <name>Calcium</name>
      <description>The risk or severity of adverse effects can be increased when Calcium is combined with Becocalcidiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06724</drugbank-id>
      <name>Calcium carbonate</name>
      <description>The risk or severity of adverse effects can be increased when Calcium carbonate is combined with Becocalcidiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11093</drugbank-id>
      <name>Calcium Citrate</name>
      <description>The risk or severity of adverse effects can be increased when Calcium Citrate is combined with Becocalcidiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11126</drugbank-id>
      <name>Calcium gluconate</name>
      <description>The risk or severity of adverse effects can be increased when Calcium gluconate is combined with Becocalcidiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11348</drugbank-id>
      <name>Calcium Phosphate</name>
      <description>The risk or severity of adverse effects can be increased when Calcium Phosphate is combined with Becocalcidiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13142</drugbank-id>
      <name>Calcium glubionate anhydrous</name>
      <description>The risk or severity of adverse effects can be increased when Calcium glubionate anhydrous is combined with Becocalcidiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13231</drugbank-id>
      <name>Calcium lactate</name>
      <description>The risk or severity of adverse effects can be increased when Calcium lactate is combined with Becocalcidiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13365</drugbank-id>
      <name>Calcium lactate gluconate</name>
      <description>The risk or severity of adverse effects can be increased when Calcium lactate gluconate is combined with Becocalcidiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13590</drugbank-id>
      <name>Calcium pangamate</name>
      <description>The risk or severity of adverse effects can be increased when Calcium pangamate is combined with Becocalcidiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13800</drugbank-id>
      <name>Calcium levulinate</name>
      <description>The risk or severity of adverse effects can be increased when Calcium levulinate is combined with Becocalcidiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14577</drugbank-id>
      <name>Calcium cation</name>
      <description>The risk or severity of adverse effects can be increased when Calcium cation is combined with Becocalcidiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14684</drugbank-id>
      <name>Calcium polycarbophil</name>
      <description>The risk or severity of adverse effects can be increased when Calcium polycarbophil is combined with Becocalcidiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00375</drugbank-id>
      <name>Colestipol</name>
      <description>The serum concentration of Becocalcidiol can be decreased when it is combined with Colestipol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00658</drugbank-id>
      <name>Sevelamer</name>
      <description>The serum concentration of Becocalcidiol can be decreased when it is combined with Sevelamer.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00930</drugbank-id>
      <name>Colesevelam</name>
      <description>The serum concentration of Becocalcidiol can be decreased when it is combined with Colesevelam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01432</drugbank-id>
      <name>Cholestyramine</name>
      <description>The serum concentration of Becocalcidiol can be decreased when it is combined with Cholestyramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00180</drugbank-id>
      <name>Flunisolide</name>
      <description>The therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Flunisolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00394</drugbank-id>
      <name>Beclomethasone dipropionate</name>
      <description>The therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Beclomethasone dipropionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00443</drugbank-id>
      <name>Betamethasone</name>
      <description>The therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Betamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00588</drugbank-id>
      <name>Fluticasone propionate</name>
      <description>The therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Fluticasone propionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00591</drugbank-id>
      <name>Fluocinolone acetonide</name>
      <description>The therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Fluocinolone acetonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00620</drugbank-id>
      <name>Triamcinolone</name>
      <description>The therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Triamcinolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00635</drugbank-id>
      <name>Prednisone</name>
      <description>The therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Prednisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00687</drugbank-id>
      <name>Fludrocortisone</name>
      <description>The therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Fludrocortisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00741</drugbank-id>
      <name>Hydrocortisone</name>
      <description>The therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Hydrocortisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00764</drugbank-id>
      <name>Mometasone</name>
      <description>The therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Mometasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00860</drugbank-id>
      <name>Prednisolone</name>
      <description>The therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Prednisolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00959</drugbank-id>
      <name>Methylprednisolone</name>
      <description>The therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Methylprednisolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01108</drugbank-id>
      <name>Trilostane</name>
      <description>The therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Trilostane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01222</drugbank-id>
      <name>Budesonide</name>
      <description>The therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Budesonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01234</drugbank-id>
      <name>Dexamethasone</name>
      <description>The therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01285</drugbank-id>
      <name>Corticotropin</name>
      <description>The therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Corticotropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01380</drugbank-id>
      <name>Cortisone acetate</name>
      <description>The therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Cortisone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01384</drugbank-id>
      <name>Paramethasone</name>
      <description>The therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Paramethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01410</drugbank-id>
      <name>Ciclesonide</name>
      <description>The therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Ciclesonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04630</drugbank-id>
      <name>Aldosterone</name>
      <description>The therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Aldosterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08906</drugbank-id>
      <name>Fluticasone furoate</name>
      <description>The therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Fluticasone furoate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08970</drugbank-id>
      <name>Fluprednidene</name>
      <description>The therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Fluprednidene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08971</drugbank-id>
      <name>Fluocortolone</name>
      <description>The therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Fluocortolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09091</drugbank-id>
      <name>Tixocortol</name>
      <description>The therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Tixocortol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09378</drugbank-id>
      <name>Fluprednisolone</name>
      <description>The therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Fluprednisolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09383</drugbank-id>
      <name>Meprednisone</name>
      <description>The therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Meprednisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11487</drugbank-id>
      <name>Dexamethasone isonicotinate</name>
      <description>The therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Dexamethasone isonicotinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11529</drugbank-id>
      <name>Melengestrol</name>
      <description>The therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Melengestrol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11750</drugbank-id>
      <name>Clobetasol</name>
      <description>The therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Clobetasol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11921</drugbank-id>
      <name>Deflazacort</name>
      <description>The therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Deflazacort.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13003</drugbank-id>
      <name>Cortivazol</name>
      <description>The therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Cortivazol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13208</drugbank-id>
      <name>Prednylidene</name>
      <description>The therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Prednylidene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13223</drugbank-id>
      <name>Fluocortin</name>
      <description>The therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Fluocortin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13491</drugbank-id>
      <name>Fluperolone</name>
      <description>The therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Fluperolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13664</drugbank-id>
      <name>Formocortal</name>
      <description>The therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Formocortal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13728</drugbank-id>
      <name>Halometasone</name>
      <description>The therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Halometasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13843</drugbank-id>
      <name>Cloprednol</name>
      <description>The therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Cloprednol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13856</drugbank-id>
      <name>Fluclorolone</name>
      <description>The therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Fluclorolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13867</drugbank-id>
      <name>Fluticasone</name>
      <description>The therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Fluticasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14512</drugbank-id>
      <name>Mometasone furoate</name>
      <description>The therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Mometasone furoate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14538</drugbank-id>
      <name>Hydrocortisone aceponate</name>
      <description>The therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Hydrocortisone aceponate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14539</drugbank-id>
      <name>Hydrocortisone acetate</name>
      <description>The therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Hydrocortisone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14541</drugbank-id>
      <name>Hydrocortisone cypionate</name>
      <description>The therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Hydrocortisone cypionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14545</drugbank-id>
      <name>Hydrocortisone succinate</name>
      <description>The therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Hydrocortisone succinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00873</drugbank-id>
      <name>Loteprednol</name>
      <description>The therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Loteprednol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14631</drugbank-id>
      <name>Prednisolone phosphate</name>
      <description>The therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Prednisolone phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14633</drugbank-id>
      <name>Prednisolone hemisuccinate</name>
      <description>The therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Prednisolone hemisuccinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14634</drugbank-id>
      <name>Fluprednidene acetate</name>
      <description>The therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Fluprednidene acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14643</drugbank-id>
      <name>Methylprednisolone aceponate</name>
      <description>The therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Methylprednisolone aceponate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14644</drugbank-id>
      <name>Methylprednisolone hemisuccinate</name>
      <description>The therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Methylprednisolone hemisuccinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14646</drugbank-id>
      <name>Prednisone acetate</name>
      <description>The therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Prednisone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14652</drugbank-id>
      <name>Clocortolone acetate</name>
      <description>The therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Clocortolone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14659</drugbank-id>
      <name>Melengestrol acetate</name>
      <description>The therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Melengestrol acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14669</drugbank-id>
      <name>Betamethasone phosphate</name>
      <description>The therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Betamethasone phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14681</drugbank-id>
      <name>Cortisone</name>
      <description>The therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Cortisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00310</drugbank-id>
      <name>Chlorthalidone</name>
      <description>The risk or severity of hypokalemia can be increased when Becocalcidiol is combined with Chlorthalidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00524</drugbank-id>
      <name>Metolazone</name>
      <description>The risk or severity of hypokalemia can be increased when Becocalcidiol is combined with Metolazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00808</drugbank-id>
      <name>Indapamide</name>
      <description>The risk or severity of hypokalemia can be increased when Becocalcidiol is combined with Indapamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01325</drugbank-id>
      <name>Quinethazone</name>
      <description>The risk or severity of hypokalemia can be increased when Becocalcidiol is combined with Quinethazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13989</drugbank-id>
      <name>Epitizide</name>
      <description>The risk or severity of hypokalemia can be increased when Becocalcidiol is combined with Epitizide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12147</drugbank-id>
      <name>Erdafitinib</name>
      <description>The risk or severity of adverse effects can be increased when Becocalcidiol is combined with Erdafitinib.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>5.35</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-4.6</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>9.70e-03 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>4.43</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>(1R,3R)-5-{2-[(1R,3aS,4E,7aR)-1-[(2S)-butan-2-yl]-7a-methyl-octahydro-1H-inden-4-ylidene]ethylidene}-2-methylidenecyclohexane-1,3-diol</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>(1R,3R)-5-{2-[(1R,3aS,4E,7aR)-1-[(2S)-butan-2-yl]-7a-methyl-hexahydro-1H-inden-4-ylidene]ethylidene}-2-methylidenecyclohexane-1,3-diol</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>344.5307</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>344.271530396</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>CC[C@@](C)([H])[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1/C[C@](O)([H])C(=C)[C@]([H])(O)C1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C23H36O2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C23H36O2/c1-5-15(2)19-10-11-20-18(7-6-12-23(19,20)4)9-8-17-13-21(24)16(3)22(25)14-17/h8-9,15,19-22,24-25H,3,5-7,10-14H2,1-2,4H3/b18-9+/t15-,19+,20-,21+,22+,23+/m0/s1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>QSLUXQQUPXBIHH-YHSKWIAJSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>40.46</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>106.23</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>42.66</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>14.19</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>-3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>5289547</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>175426893</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>4451487</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PDB</resource>
      <identifier>VD1</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL2104955</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0004382</id>
      <name>Mediator of RNA polymerase II transcription subunit 1</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A1991</ref-id>
            <pubmed-id>10592235</pubmed-id>
            <citation>Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q15648" source="Swiss-Prot">
        <name>Mediator of RNA polymerase II transcription subunit 1</name>
        <general-function>Vitamin d receptor binding</general-function>
        <specific-function>Component of the Mediator complex, a coactivator involved in the regulated transcription of nearly all RNA polymerase II-dependent genes. Mediator functions as a bridge to convey information from gene-specific regulatory proteins to the basal RNA polymerase II transcription machinery. Mediator is recruited to promoters by direct interactions with regulatory proteins and serves as a scaffold for the assembly of a functional preinitiation complex with RNA polymerase II and the general transcription factors (PubMed:10406464, PubMed:11867769, PubMed:12037571, PubMed:12218053, PubMed:12556447, PubMed:14636573, PubMed:15340084, PubMed:15471764, PubMed:15989967, PubMed:16574658, PubMed:9653119). Acts as a coactivator for GATA1-mediated transcriptional activation during erythroid differentiation of K562 erythroleukemia cells (PubMed:24245781).</specific-function>
        <gene-name>MED1</gene-name>
        <locus>17q12-q21.1</locus>
        <cellular-location>Nucleus</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>9.1</theoretical-pi>
        <molecular-weight>168476.57</molecular-weight>
        <chromosome-location>17</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:9234</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>Y13467</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>2765322</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q15648</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>MED1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Activator-recruited cofactor 205 kDa component</synonym>
          <synonym>ARC205</synonym>
          <synonym>CRSP1</synonym>
          <synonym>CRSP200</synonym>
          <synonym>DRIP205</synonym>
          <synonym>DRIP230</synonym>
          <synonym>Mediator complex subunit 1</synonym>
          <synonym>p53 regulatory protein RB18A</synonym>
          <synonym>PBP</synonym>
          <synonym>Peroxisome proliferator-activated receptor-binding protein</synonym>
          <synonym>PPAR-binding protein</synonym>
          <synonym>PPARBP</synonym>
          <synonym>PPARGBP</synonym>
          <synonym>RB18A</synonym>
          <synonym>Thyroid hormone receptor-associated protein complex 220 kDa component</synonym>
          <synonym>Thyroid receptor-interacting protein 2</synonym>
          <synonym>TR-interacting protein 2</synonym>
          <synonym>TRAP220</synonym>
          <synonym>TRIP-2</synonym>
          <synonym>TRIP2</synonym>
          <synonym>Vitamin D receptor-interacting protein complex component DRIP205</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0008320|Mediator of RNA polymerase II transcription subunit 1
MKAQGETEESEKLSKMSSLLERLHAKFNQNRPWSETIKLVRQVMEKRVVMSSGGHQHLVS
CLETLQKALKVTSLPAMTDRLESIARQNGLGSHLSASGTECYITSDMFYVEVQLDPAGQL
CDVKVAHHGENPVSCPELVQQLREKNFDEFSKHLKGLVNLYNLPGDNKLKTKMYLALQSL
EQDLSKMAIMYWKATNAGPLDKILHGSVGYLTPRSGGHLMNLKYYVSPSDLLDDKTASPI
ILHENNVSRSLGMNASVTIEGTSAVYKLPIAPLIMGSHPVDNKWTPSFSSITSANSVDLP
ACFFLKFPQPIPVSRAFVQKLQNCTGIPLFETQPTYAPLYELITQFELSKDPDPIPLNHN
MRFYAALPGQQHCYFLNKDAPLPDGRSLQGTLVSKITFQHPGRVPLILNLIRHQVAYNTL
IGSCVKRTILKEDSPGLLQFEVCPLSESRFSVSFQHPVNDSLVCVVMDVQDSTHVSCKLY
KGLSDALICTDDFIAKVVQRCMSIPVTMRAIRRKAETIQADTPALSLIAETVEDMVKKNL
PPASSPGYGMTTGNNPMSGTTTPTNTFPGGPITTLFNMSMSIKDRHESVGHGEDFSKVSQ
NPILTSLLQITGNGGSTIGSSPTPPHHTPPPVSSMAGNTKNHPMLMNLLKDNPAQDFSTL
YGSSPLERQNSSSGSPRMEICSGSNKTKKKKSSRLPPEKPKHQTEDDFQRELFSMDVDSQ
NPIFDVNMTADTLDTPHITPAPSQCSTPPTTYPQPVPHPQPSIQRMVRLSSSDSIGPDVT
DILSDIAEEASKLPSTSDDCPAIGTPLRDSSSSGHSQSTLFDSDVFQTNNNENPYTDPAD
LIADAAGSPSSDSPTNHFFHDGVDFNPDLLNSQSQSGFGEEYFDESSQSGDNDDFKGFAS
QALNTLGVPMLGGDNGETKFKGNNQADTVDFSIISVAGKALAPADLMEHHSGSQGPLLTT
GDLGKEKTQKRVKEGNGTSNSTLSGPGLDSKPGKRSRTPSNDGKSKDKPPKRKKADTEGK
SPSHSSSNRPFTPPTSTGGSKSPGSAGRSQTPPGVATPPIPKITIQIPKGTVMVGKPSSH
SQYTSSGSVSSSGSKSHHSHSSSSSSSASTSGKMKSSKSEGSSSSKLSSSMYSSQGSSGS
SQSKNSSQSGGKPGSSPITKHGLSSGSSSTKMKPQGKPSSLMNPSLSKPNISPSHSRPPG
GSDKLASPMKPVPGTPPSSKAKSPISSGSGGSHMSGTSSSSGMKSSSGLGSSGSLSQKTP
PSSNSCTASSSSFSSSGSSMSSSQNQHGSSKGKSPSRNKKPSLTAVIDKLKHGVVTSGPG
GEDPLDGQMGVSTNSSSHPMSSKHNMSGGEFQGKREKSDKDKSKVSTSGSSVDSSKKTSE
SKNVGSTGVAKIIISKHDGGSPSIKAKVTLQKPGESSGEGLRPQMASSKNYGSPLISGST
PKHERGSPSHSKSPAYTPQNLDSESESGSSIAEKSYQNSPSSDDGIRPLPEYSTEKHKKH
KKEKKKVKDKDRDRDRDKDRDKKKSHSIKPESWSKSPISSDQSLSMTSNTILSADRPSRL
SPDFMIGEEDDDLMDVALIGN</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0013052|Mediator of RNA polymerase II transcription subunit 1 (MED1)
ATGAAAGCTCAGGGGGAAACCGAGGAGTCAGAAAAGCTGAGTAAGATGAGTTCTCTCCTG
GAACGGCTCCATGCAAAATTTAACCAAAATAGACCCTGGAGTGAAACCATTAAGCTTGTG
CGTCAAGTCATGGAGAAGAGGGTTGTGATGAGTTCTGGAGGGCATCAACATTTGGTCAGC
TGTTTGGAGACATTGCAGAAGGCTCTCAAAGTAACATCTTTACCAGCAATGACTGATCGT
TTGGAGTCCATAGCAAGACAGAATGGACTGGGCTCTCATCTCAGTGCCAGTGGCACTGAA
TGTTACATCACGTCAGATATGTTCTATGTGGAAGTGCAGTTAGATCCTGCAGGACAGCTT
TGTGATGTAAAAGTGGCTCACCATGGGGAGAATCCTGTGAGCTGTCCGGAGCTTGTACAG
CAGCTAAGGGAAAAAAATTTTGATGAATTTTCTAAGCACCTTAAGGGCCTTGTTAATCTG
TATAACCTTCCAGGGGACAACAAACTGAAGACTAAAATGTACTTGGCTCTCCAATCCTTA
GAACAAGATCTTTCTAAAATGGCAATTATGTACTGGAAAGCAACTAATGCTGGTCCCTTG
GATAAGATTCTTCATGGAAGTGTTGGCTATCTCACACCAAGGAGTGGGGGTCATTTAATG
AACCTGAAGTACTATGTCTCTCCTTCTGACCTACTGGATGACAAGACTGCATCTCCCATC
ATTTTGCATGAGAATAATGTTTCTCGATCTTTGGGCATGAATGCATCAGTGACAATTGAA
GGAACATCTGCTGTGTACAAACTCCCAATTGCACCATTAATTATGGGGTCACATCCAGTT
GACAATAAATGGACCCCTTCCTTCTCCTCAATCACCAGTGCCAACAGTGTTGATCTTCCT
GCCTGTTTCTTCTTGAAATTTCCCCAGCCAATCCCAGTATCTAGAGCATTTGTTCAGAAA
CTGCAGAACTGCACAGGAATTCCATTGTTTGAAACTCAACCAACTTATGCACCCCTGTAT
GAACTGATCACTCAGTTTGAGCTATCAAAGGACCCTGACCCCATACCTTTGAATCACAAC
ATGAGATTTTATGCTGCTCTTCCTGGTCAGCAGCACTGCTATTTCCTCAACAAGGATGCT
CCTCTTCCAGATGGCCGAAGTCTACAGGGAACCCTTGTTAGCAAAATCACCTTTCAGCAC
CCTGGCCGAGTTCCTCTTATCCTAAATCTGATCAGACACCAAGTGGCCTATAACACCCTC
ATTGGAAGCTGTGTCAAAAGAACTATTCTGAAAGAAGATTCTCCTGGGCTTCTCCAATTT
GAAGTGTGTCCTCTCTCAGAGTCTCGTTTCAGCGTATCTTTTCAGCACCCTGTGAATGAC
TCCCTGGTGTGTGTGGTAATGGATGTGCAGGACTCAACACATGTGAGCTGTAAACTCTAC
AAAGGGCTGTCGGATGCACTGATCTGCACAGATGACTTCATTGCCAAAGTTGTTCAAAGA
TGTATGTCCATCCCTGTGACGATGAGGGCTATTCGGAGGAAAGCTGAAACCATTCAAGCC
GACACCCCAGCACTGTCCCTCATTGCAGAGACAGTTGAAGACATGGTGAAAAAGAACCTG
CCCCCGGCTAGCAGCCCAGGGTATGGCATGACCACAGGCAACAACCCAATGAGTGGTACC
ACTACACCAACCAACACCTTTCCGGGGGGTCCCATTACCACCTTGTTTAATATGAGCATG
AGCATCAAAGATCGGCATGAGTCGGTGGGCCATGGGGAGGACTTCAGCAAGGTGTCTCAG
AACCCAATTCTTACCAGTTTGTTGCAAATCACAGGGAACGGGGGGTCTACCATTGGCTCG
AGTCCGACCCCTCCTCATCACACGCCGCCACCTGTCTCTTCGATGGCCGGCAACACCAAG
AACCACCCGATGCTCATGAACCTTCTTAAAGATAATCCTGCCCAGGATTTCTCAACCCTT
TATGGAAGCAGCCCTTTAGAAAGGCAGAACTCCTCTTCCGGCTCACCCCGCATGGAAATA
TGCTCGGGGAGCAACAAGACCAAGAAAAAGAAGTCATCAAGATTACCACCTGAGAAACCA
AAGCACCAGACTGAAGATGACTTTCAGAGGGAGCTATTTTCAATGGATGTTGACTCACAG
AACCCTATCTTTGATGTCAACATGACAGCTGACACGCTGGATACGCCACACATCACTCCA
GCTCCAAGCCAGTGTAGCACTCCCCCAACAACTTACCCACAACCAGTACCTCACCCCCAA
CCCAGTATTCAAAGGATGGTCCGACTATCCAGTTCAGACAGCATTGGCCCAGATGTAACT
GACATCCTTTCAGACATTGCAGAAGAAGCTTCTAAACTTCCCAGCACTAGTGATGATTGC
CCAGCCATTGGCACCCCTCTTCGAGATTCTTCAAGCTCTGGGCATTCTCAGAGTACCCTG
TTTGACTCTGATGTCTTTCAAACTAACAATAATGAAAATCCATACACTGATCCAGCTGAT
CTTATTGCAGATGCTGCTGGAAGCCCCAGTAGTGACTCTCCTACCAATCATTTTTTTCAT
GATGGAGTAGATTTCAATCCTGATTTATTGAACAGCCAGAGCCAAAGTGGTTTTGGAGAA
GAATATTTTGATGAAAGCAGCCAAAGTGGGGATAATGATGATTTCAAAGGATTTGCATCT
CAGGCACTAAATACTTTGGGGGTGCCAATGCTTGGAGGTGATAATGGGGAGACCAAGTTT
AAGGGCAATAACCAAGCCGACACAGTTGATTTCAGTATTATTTCAGTAGCCGGCAAAGCT
TTAGCTCCTGCAGATCTTATGGAGCATCACAGTGGTAGTCAGGGTCCTTTACTGACCACT
GGGGACTTAGGGAAAGAAAAGACTCAAAAGAGGGTAAAGGAAGGCAATGGCACCAGTAAT
AGTACTCTCTCGGGGCCCGGATTAGACAGCAAACCAGGGAAGCGCAGTCGGACCCCTTCT
AATGATGGGAAAAGCAAAGATAAGCCTCCAAAGCGGAAGAAGGCAGACACTGAGGGAAAG
TCTCCATCTCATAGTTCTTCTAACAGACCTTTTACCCCACCTACCAGTACAGGTGGATCT
AAATCGCCAGGCAGTGCAGGAAGATCTCAGACTCCCCCAGGTGTTGCCACACCACCCATT
CCCAAAATCACTATTCAGATTCCTAAGGGAACAGTGATGGTGGGCAAGCCTTCCTCTCAC
AGTCAGTATACCAGCAGTGGTTCTGTGTCTTCCTCAGGCAGCAAAAGCCACCATAGCCAT
TCTTCCTCCTCTTCCTCATCTGCTTCCACCTCAGGGAAGATGAAAAGCAGTAAATCAGAA
GGTTCATCAAGTTCCAAGTTAAGTAGCAGTATGTATTCTAGCCAGGGGTCTTCTGGATCT
AGCCAGTCCAAAAATTCATCCCAGTCTGGGGGGAAGCCAGGCTCCTCTCCCATAACCAAG
CATGGACTGAGCAGTGGCTCTAGCAGCACCAAGATGAAACCTCAAGGAAAGCCATCATCA
CTTATGAATCCTTCTTTAAGTAAACCAAACATATCCCCTTCTCATTCAAGGCCACCTGGA
GGCTCTGACAAGCTTGCCTCTCCAATGAAGCCTGTTCCTGGAACTCCTCCATCCTCTAAA
GCCAAGTCCCCTATCAGTTCAGGTTCTGGTGGTTCTCATATGTCTGGAACTAGTTCAAGC
TCTGGCATGAAGTCATCTTCAGGGTTAGGATCCTCAGGCTCGTTGTCCCAGAAAACTCCC
CCATCATCTAATTCCTGTACGGCATCTTCCTCCTCCTTTTCCTCAAGTGGCTCTTCCATG
TCATCCTCTCAGAACCAGCATGGGAGTTCTAAAGGAAAATCTCCCAGCAGAAACAAGAAG
CCGTCCTTGACAGCTGTCATAGATAAACTGAAGCATGGGGTTGTCACCAGTGGCCCTGGG
GGTGAAGACCCACTGGACGGCCAGATGGGGGTGAGCACAAATTCTTCCAGCCATCCTATG
TCCTCCAAACATAACATGTCAGGAGGAGAGTTTCAGGGCAAGCGTGAGAAAAGTGATAAA
GACAAATCAAAGGTTTCCACCTCCGGGAGTTCAGTGGATTCTTCTAAGAAGACCTCAGAG
TCAAAAAATGTGGGGAGCACAGGTGTGGCAAAAATTATCATCAGTAAGCATGATGGAGGC
TCCCCTAGCATTAAAGCCAAAGTGACTTTGCAGAAACCTGGGGAAAGTAGTGGAGAAGGG
CTTAGGCCTCAAATGGCTTCTTCTAAAAACTATGGCTCTCCACTCATCAGTGGTTCCACT
CCAAAGCATGAGCGTGGCTCTCCCAGCCATAGTAAGTCACCAGCATATACCCCCCAGAAT
CTGGACAGTGAAAGTGAGTCAGGCTCCTCCATAGCAGAGAAATCTTATCAGAATAGTCCC
AGCTCAGACGATGGTATCCGACCACTTCCAGAATACAGCACAGAGAAACATAAGAAGCAC
AAAAAGGAAAAGAAGAAAGTAAAAGACAAAGATAGGGACCGAGACCGGGACAAAGACCGA
GACAAGAAAAAATCTCATAGCATCAAGCCAGAGAGTTGGTCCAAATCACCCATCTCTTCA
GACCAGTCCTTGTCTATGACAAGTAACACAATCTTATCTGCAGACAGACCCTCAAGGCTC
AGCCCAGACTTTATGATTGGGGAGGAAGATGATGATCTTATGGATGTGGCCCTGATTGGG
AATTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF10744</identifier>
            <name>Med1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>chromatin</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mediator complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleolus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>protein-DNA complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>ubiquitin ligase complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>chromatin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>chromatin DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>core promoter binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>estrogen receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>LBD domain binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ligand-dependent nuclear receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ligand-dependent nuclear receptor transcription coactivator activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>mediator complex binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>nuclear hormone receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>peroxisome proliferator activated receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>retinoic acid receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>RNA polymerase II core promoter proximal region sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>RNA polymerase II transcription cofactor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>RNA polymerase II transcription factor activity, sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>thyroid hormone receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>thyroid hormone receptor coactivator activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcription coactivator activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcription cofactor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcription factor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ubiquitin protein ligase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>vitamin D receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>androgen biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>androgen receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>angiogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>brain development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell morphogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular lipid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to epidermal growth factor stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to hepatocyte growth factor stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to steroid hormone stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to thyroid hormone stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>embryonic heart tube development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>embryonic hemopoiesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>embryonic hindlimb morphogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>embryonic placenta development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>enucleate erythrocyte development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epithelial cell proliferation involved in mammary gland duct elongation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ERK1 and ERK2 cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>erythrocyte development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>fat cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>intracellular steroid hormone receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>keratinocyte differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lactation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lens development in camera-type eye</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>liver development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mammary gland branching involved in pregnancy</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mammary gland branching involved in thelarche</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>megakaryocyte development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>monocyte differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mRNA transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of keratinocyte proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of neuron differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>organ regeneration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>peroxisome proliferator activated receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of erythrocyte differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of G0 to G1 transition</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of hepatocyte proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of interferon-gamma-mediated signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of intracellular estrogen receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of keratinocyte differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of mammary gland epithelial cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of protein import into nucleus, translocation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription, DNA-templated</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cell cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of RNA biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of transcription from RNA polymerase I promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of vitamin D receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>retinal pigment epithelium development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>thyroid hormone generation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>thyroid hormone mediated signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transcription initiation from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ventricular trabecula myocardium morphogenesis</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="2">
      <id>BE0000779</id>
      <name>Vitamin D3 receptor</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A1991</ref-id>
            <pubmed-id>10592235</pubmed-id>
            <citation>Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P11473" source="Swiss-Prot">
        <name>Vitamin D3 receptor</name>
        <general-function>Zinc ion binding</general-function>
        <specific-function>Nuclear hormone receptor. Transcription factor that mediates the action of vitamin D3 by controlling the expression of hormone sensitive genes. Recruited to promoters via its interaction with BAZ1B/WSTF which mediates the interaction with acetylated histones, an essential step for VDR-promoter association. Plays a central role in calcium homeostasis.</specific-function>
        <gene-name>VDR</gene-name>
        <locus>12q13.11</locus>
        <cellular-location>Nucleus</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>6.5</theoretical-pi>
        <molecular-weight>48288.64</molecular-weight>
        <chromosome-location>12</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:12679</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>VDR</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>J03258</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>340203</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>605</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>605</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P11473</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>VDR_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1,25-dihydroxyvitamin D3 receptor</synonym>
          <synonym>NR1I1</synonym>
          <synonym>Nuclear receptor subfamily 1 group I member 1</synonym>
          <synonym>VDR</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001554|Vitamin D3 receptor
MEAMAASTSLPDPGDFDRNVPRICGVCGDRATGFHFNAMTCEGCKGFFRRSMKRKALFTC
PFNGDCRITKDNRRHCQACRLKRCVDIGMMKEFILTDEEVQRKREMILKRKEEEALKDSL
RPKLSEEQQRIIAILLDAHHKTYDPTYSDFCQFRPPVRVNDGGGSHPSRPNSRHTPSFSG
DSSSSCSDHCITSSDMMDSSSFSNLDLSEEDSDDPSVTLELSQLSMLPHLADLVSYSIQK
VIGFAKMIPGFRDLTSEDQIVLLKSSAIEVIMLRSNESFTMDDMSWTCGNQDYKYRVSDV
TKAGHSLELIEPLIKFQVGLKKLNLHEEEHVLLMAICIVSPDRPGVQDAALIEAIQDRLS
NTLQTYIRCRHPPPGSHLLYAKMIQKLADLRSLNEEHSKQYRCLSFQPECSMKLTPLVLE
VFGNEIS</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010550|Vitamin D3 receptor (VDR)
ATGGAGGCAATGGCGGCCAGCACTTCCCTGCCTGACCCTGGAGACTTTGACCGGAACGTG
CCCCGGATCTGTGGGGTGTGTGGAGACCGAGCCACTGGCTTTCACTTCAATGCTATGACC
TGTGAAGGCTGCAAAGGCTTCTTCAGGCGAAGCATGAAGCGGAAGGCACTATTCACCTGC
CCCTTCAACGGGGACTGCCGCATCACCAAGGACAACCGACGCCACTGCCAGGCCTGCCGG
CTCAAACGCTGTGTGGACATCGGCATGATGAAGGAGTTCATTCTGACAGATGAGGAAGTG
CAGAGGAAGCGGGAGATGATCCTGAAGCGGAAGGAGGAGGAGGCCTTGAAGGACAGTCTG
CGGCCCAAGCTGTCTGAGGAGCAGCAGCGCATCATTGCCATACTGCTGGACGCCCACCAT
AAGACCTACGACCCCACCTACTCCGACTTCTGCCAGTTCCGGCCTCCAGTTCGTGTGAAT
GATGGTGGAGGGAGCCATCCTTCCAGGCCCAACTCCAGACACACTCCCAGCTTCTCTGGG
GACTCCTCCTCCTCCTGCTCAGATCACTGTATCACCTCTTCAGACATGATGGACTCGTCC
AGCTTCTCCAATCTGGATCTGAGTGAAGAAGATTCAGATGACCCTTCTGTGACCCTAGAG
CTGTCCCAGCTCTCCATGCTGCCCCACCTGGCTGACCTGGTCAGTTACAGCATCCAAAAG
GTCATTGGCTTTGCTAAGATGATACCAGGATTCAGAGACCTCACCTCTGAGGACCAGATC
GTACTGCTGAAGTCAAGTGCCATTGAGGTCATCATGTTGCGCTCCAATGAGTCCTTCACC
ATGGACGACATGTCCTGGACCTGTGGCAACCAAGACTACAAGTACCGCGTCAGTGACGTG
ACCAAAGCCGGACACAGCCTGGAGCTGATTGAGCCCCTCATCAAGTTCCAGGTGGGACTG
AAGAAGCTGAACTTGCATGAGGAGGAGCATGTCCTGCTCATGGCCATCTGCATCGTCTCC
CCAGATCGTCCTGGGGTGCAGGACGCCGCGCTGATTGAGGCCATCCAGGACCGCCTGTCC
AACACACTGCAGACGTACATCCGCTGCCGCCACCCGCCCCCGGGCAGCCACCTGCTCTAT
GCCAAGATGATCCAGAAGCTAGCCGACCTGCGCAGCCTCAATGAGGAGCACTCCAAGCAG
TACCGCTGCCTCTCCTTCCAGCCTGAGTGCAGCATGAAGCTAACGCCCCTTGTGCTCGAA
GTGTTTGGCAATGAGATCTCCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00104</identifier>
            <name>Hormone_recep</name>
          </pfam>
          <pfam>
            <identifier>PF00105</identifier>
            <name>zf-C4</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>nucleoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>receptor complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>RNA polymerase II transcription factor complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calcitriol binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calcitriol receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>lithocholic acid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>lithocholic acid receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>retinoid X receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hormone receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>zinc ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bile acid signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell morphogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular calcium ion homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>decidualization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>intestinal absorption</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lactation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mammary gland branching involved in pregnancy</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of keratinocyte proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of transcription, DNA-templated</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of apoptotic process involved in mammary gland involution</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of keratinocyte differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of vitamin D 24-hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of calcidiol 1-monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>skeletal system development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transcription initiation from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vitamin D receptor signaling pathway</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>